{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:38:49Z","timestamp":1783384729519,"version":"3.54.6"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec011\">\n                    <jats:title>Background and objective<\/jats:title>\n                    <jats:p>Device-aided therapies (DATs) are treatments indicated for people with Parkinson\u00b4s disease (PwP) experiencing clinical fluctuations that remain suboptimal despite conventional medication. New DATs have recently emerged such as levodopa-entacapone-carbidopa intestinal gel infusion (LECIG) and subcutaneous infusion of foslevodopa\/foscarbidopa (fLD\/fCD). Understanding the differences between various DATs is essential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec012\">\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>We present here the protocol study of the DATs-PD GETM Spanish Registry. This is a descriptive, observational, prospective, multicenter, open study that is proposed as a clinical registry with progressive inclusion of PwP treated with a DAT in daily clinical practice conditions in more 40 centers from Spain for 10 years. The principal aim is to know the type of DAT that PwP in our country (Spain) receive. Specific objectives are to compare the clinical characteristics of the patients, the effectiveness, safety and tolerability, to identify predictors of a good response and to analyze the response by groups (gender, disease duration, phenotype, etc.). There is a baseline visit (V1; indication of the therapy), start visit (V2; initiation of the therapy) and follow-up visits at 6 months \u00b1\u2009 3 months (V3_6M) and after this annually \u00b1\u2009 3 months for 10 years (V3_12M, V3_24M, etc.).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec013\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The registry is on going. The first patient was included on April 10, 2024. Patient recruitment and follow-up will be conducted until 31\/DEC\/2033. It is estimated that the registry will include a minimum of 3,000 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec014\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present study will help improve the care of PD patients treated with a DAT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0316052","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T15:50:40Z","timestamp":1743436240000},"page":"e0316052","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Device-aided therapies (DATs) in Parkinson\u2019s disease (PD). The DATs-PD GETM Spanish Registry Protocol Study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-5111","authenticated-orcid":true,"given":"Diego","family":"Santos-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Gonz\u00e1lez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"S\u00e1nchez-Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8137-0622","authenticated-orcid":true,"given":"Anna","family":"Planas-Ballv\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Garc\u00eda-Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iria","family":"Cabo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bl\u00e1zquez-Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"S\u00e1nchez-Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"DATs-P. D. GETM Spanish Registry Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"10291","key":"pone.0316052.ref001","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s disease","volume":"397","author":"BR Bloem","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"pone.0316052.ref002","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1136\/jnnp.55.3.181","article-title":"Accuracy of clinical diagnosis of idiopathic Parkinson\u2019s disease: a clinico-pathological study of 100 cases","volume":"55","author":"AJ Hughes","year":"1992","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"pone.0316052.ref003","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"RB Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"pone.0316052.ref004","doi-asserted-by":"crossref","first-page":"105852","DOI":"10.1016\/j.parkreldis.2023.105852","article-title":"Response to levodopa in Parkinson\u2019s disease over time. A 4-year follow-up study","volume":"116","author":"D Santos-Garc\u00eda","year":"2023","journal-title":"Parkinsonism Relat Disord"},{"issue":"12","key":"pone.0316052.ref005","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1001\/archneur.63.12.1756","article-title":"Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease","volume":"63","author":"RA Hauser","year":"2006","journal-title":"Arch Neurol"},{"key":"pone.0316052.ref006","doi-asserted-by":"crossref","first-page":"1149615","DOI":"10.3389\/fneur.2023.1149615","article-title":"Impact of non-motor fluctuations on QOL in patients with Parkinson\u2019s disease","volume":"14","author":"A Kakimoto","year":"2023","journal-title":"Front Neurol"},{"issue":"7","key":"pone.0316052.ref007","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1002\/mds.29066","article-title":"European Academy of Neurology\/Movement Disorder Society-European Section guideline on the treatment of Parkinson\u2019s disease: I. Invasive therapies","volume":"37","author":"G Deuschl","year":"2022","journal-title":"Mov Disord"},{"issue":"11","key":"pone.0316052.ref008","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00702-023-02656-z","article-title":"Tools and criteria to select patients with advanced Parkinson\u2019s disease for device-aided therapies: a narrative review","volume":"130","author":"HR Moes","year":"2023","journal-title":"J Neural Transm (Vienna)"},{"issue":"11","key":"pone.0316052.ref009","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00702-024-02782-2","article-title":"What was first and what is next in selecting device-aided therapy in Parkinson\u2019s disease? Balancing evidence and experience","volume":"131","author":"O Phokaewvarangkul","year":"2024","journal-title":"J Neural Transm (Vienna)"},{"issue":"11","key":"pone.0316052.ref010","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00702-023-02668-9","article-title":"Access to device-aided therapies in advanced Parkinson\u2019s disease: navigating clinician biases, patient preference, and prognostic uncertainty","volume":"130","author":"M Auffret","year":"2023","journal-title":"J Neural Transm (Vienna)"},{"key":"pone.0316052.ref011","article-title":"Effectiveness and safety of levodopa-entacapone-carbidopa infusion in Parkinson disease: A real-world data study","author":"D Santos-Garc\u00eda","year":"2024","journal-title":"Eur J Neurol"},{"issue":"12","key":"pone.0316052.ref012","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","article-title":"Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial","volume":"21","author":"MJ Soileau","year":"2022","journal-title":"Lancet Neurol"},{"issue":"11","key":"pone.0316052.ref013","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00702-023-02693-8","article-title":"Current and novel infusion therapies for patients with Parkinson\u2019s disease","volume":"130","author":"A Antonini","year":"2023","journal-title":"J Neural Transm (Vienna)"},{"issue":"10","key":"pone.0316052.ref014","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1002\/mdc3.14161","article-title":"Continuous subcutaneous foslevodopa-foscarbidopa in parkinson\u2019s disease: a mini-review of current scope and future outlook","volume":"11","author":"M Aubignat","year":"2024","journal-title":"Mov Disord Clin Pract"},{"issue":"1","key":"pone.0316052.ref015","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s42466-021-00157-6","article-title":"An updated calculator for determining levodopa-equivalent dose","volume":"3","author":"D Nyholm","year":"2021","journal-title":"Neurol Res Pract"},{"issue":"3","key":"pone.0316052.ref016","first-page":"189","article-title":"\u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"MF Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"issue":"4","key":"pone.0316052.ref017","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"ZS Nasreddine","year":"2005","journal-title":"J Am Geriatr Soc"},{"issue":"7","key":"pone.0316052.ref018","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/mds.22007","article-title":"Parkinson\u2019s disease-cognitive rating scale: a new cognitive scale specific for Parkinson\u2019s disease","volume":"23","author":"J Pagonabarraga","year":"2008","journal-title":"Mov Disord"},{"key":"pone.0316052.ref019","first-page":"153","article-title":"Unified parkinson\u2019s disease rating scale","volume-title":"Recent Dev Parkinson\u2019s Dis","author":"Members of the UPDRS Development Committee","year":"1987"},{"issue":"5","key":"pone.0316052.ref020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"MM Hoehn","year":"1967","journal-title":"Neurology"},{"issue":"1","key":"pone.0316052.ref021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3390\/diagnostics12010055","article-title":"MNCD: a new tool for classifying parkinson\u2019s disease in daily clinical practice","volume":"12","author":"D Santos Garc\u00eda","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"5","key":"pone.0316052.ref022","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ageing\/26.5.353","article-title":"The Parkinson\u2019s Disease Questionnaire (PDQ-39): development and validation of a Parkinson\u2019s disease summary index score","volume":"26","author":"C Jenkinson","year":"1997","journal-title":"Age Ageing"},{"issue":"3","key":"pone.0316052.ref023","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jval.2011.11.035","article-title":"The EUROHIS-QOL 8-item index: comparative psychometric properties to its parent WHOQOL-BREF","volume":"15","author":"NS da Rocha","year":"2012","journal-title":"Value Health"},{"key":"pone.0316052.ref024","first-page":"152","article-title":"In Third Symposium on Parkinson\u2019s disease","volume-title":"Third Symposium on Parkinson\u2019s disease","author":"R Schwab","year":"1969"},{"issue":"15","key":"pone.0316052.ref025","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"CG Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"pone.0316052.ref026","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12883-016-0548-9","article-title":"COPPADIS-2015 (COhort of Patients with PArkinson\u2019s DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson\u2019s disease progression","volume":"16","author":"D Santos-Garc\u00eda","year":"2016","journal-title":"BMC Neurol"},{"issue":"12","key":"pone.0316052.ref027","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.3390\/brainsci11121557","article-title":"Prevalence of advanced parkinson\u2019s disease in patients treated in the hospitals of the spanish national healthcare system: the PARADISE Study","volume":"11","author":"JC Mart\u00ednez-Castrillo","year":"2021","journal-title":"Brain Sci"},{"key":"pone.0316052.ref028","article-title":"Long-term evolution of advanced Parkinson\u2019s disease burden: Subgroup analysis from the 24 month international PROSPECT observational study","volume":"39","author":"O de Fabregues","year":"2024","journal-title":"Mov Disord"},{"issue":"4","key":"pone.0316052.ref029","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1097\/WCO.0000000000001277","article-title":"Levodopa infusion therapies for Parkinson disease","volume":"37","author":"MN Dean","year":"2024","journal-title":"Curr Opin Neurol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T15:51:45Z","timestamp":1743436305000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316052"}},"subtitle":[],"editor":[{"given":"Barry","family":"Kweh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,31]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0316052","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.07.24318643","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]}}}